1
|
Azzi J, Geara AS, El-Sayegh S, Abdi R. Immunological aspects of pancreatic islet cell transplantation. Expert Rev Clin Immunol 2014; 6:111-24. [DOI: 10.1586/eci.09.67] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
2
|
Huurman VAL, Hilbrands R, Pinkse GGM, Gillard P, Duinkerken G, van de Linde P, van der Meer-Prins PMW, Versteeg-van der Voort Maarschalk MFJ, Verbeeck K, Alizadeh BZ, Mathieu C, Gorus FK, Roelen DL, Claas FHJ, Keymeulen B, Pipeleers DG, Roep BO. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One 2008; 3:e2435. [PMID: 18560516 PMCID: PMC2426735 DOI: 10.1371/journal.pone.0002435] [Citation(s) in RCA: 161] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2007] [Accepted: 04/22/2008] [Indexed: 02/04/2023] Open
Abstract
Background Islet cell transplantation can cure type 1 diabetes (T1D), but only a minority of recipients remains insulin–independent in the following years. We tested the hypothesis that allograft rejection and recurrent autoimmunity contribute to this progressive loss of islet allograft function. Methodology/Principal Findings Twenty-one T1D patients received cultured islet cell grafts prepared from multiple donors and transplanted under anti-thymocyte globulin (ATG) induction and tacrolimus plus mycophenolate mofetil (MMF) maintenance immunosuppression. Immunity against auto- and alloantigens was measured before and during one year after transplantation. Cellular auto- and alloreactivity was assessed by lymphocyte stimulation tests against autoantigens and cytotoxic T lymphocyte precursor assays, respectively. Humoral reactivity was measured by auto- and alloantibodies. Clinical outcome parameters - including time until insulin independence, insulin independence at one year, and C-peptide levels over one year- remained blinded until their correlation with immunological parameters. All patients showed significant improvement of metabolic control and 13 out of 21 became insulin-independent. Multivariate analyses showed that presence of cellular autoimmunity before and after transplantation is associated with delayed insulin-independence (p = 0.001 and p = 0.01, respectively) and lower circulating C-peptide levels during the first year after transplantation (p = 0.002 and p = 0.02, respectively). Seven out of eight patients without pre-existent T-cell autoreactivity became insulin-independent, versus none of the four patients reactive to both islet autoantigens GAD and IA-2 before transplantation. Autoantibody levels and cellular alloreactivity had no significant association with outcome. Conclusions/Significance In this cohort study, cellular islet-specific autoimmunity associates with clinical outcome of islet cell transplantation under ATG-tacrolimus-MMF immunosuppression. Tailored immunotherapy targeting cellular islet autoreactivity may be required. Monitoring cellular immune reactivity can be useful to identify factors influencing graft survival and to assess efficacy of immunosuppression. Trial Registration Clinicaltrials.gov NCT00623610
Collapse
Affiliation(s)
- Volkert A. L. Huurman
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Robert Hilbrands
- Diabetes Research Center, Brussels Free University-VUB, Brussels, Belgium
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Gabriëlle G. M. Pinkse
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Pieter Gillard
- Diabetes Research Center, Brussels Free University-VUB, Brussels, Belgium
- Laboratory for Experimental Medicine & Endocrinology (LEGENDO), University Hospital Gasthuisberg, Catholic University of Leuven-KUL, Leuven, Belgium
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Gaby Duinkerken
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Pieter van de Linde
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Petronella M. W. van der Meer-Prins
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | | | - Koen Verbeeck
- Diabetes Research Center, Brussels Free University-VUB, Brussels, Belgium
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Behrooz Z. Alizadeh
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Chantal Mathieu
- Laboratory for Experimental Medicine & Endocrinology (LEGENDO), University Hospital Gasthuisberg, Catholic University of Leuven-KUL, Leuven, Belgium
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Frans K. Gorus
- Diabetes Research Center, Brussels Free University-VUB, Brussels, Belgium
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Dave L. Roelen
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Frans H. J. Claas
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Bart Keymeulen
- Diabetes Research Center, Brussels Free University-VUB, Brussels, Belgium
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Daniel G. Pipeleers
- Diabetes Research Center, Brussels Free University-VUB, Brussels, Belgium
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
| | - Bart O. Roep
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
- JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
- * E-mail:
| |
Collapse
|
3
|
Papeta N, Chen T, Vianello F, Gererty L, Malik A, Mok YT, Tharp WG, Bagley J, Zhao G, Stevceva L, Yoon V, Sykes M, Sachs D, Iacomini J, Poznansky MC. Long-term survival of transplanted allogeneic cells engineered to express a T cell chemorepellent. Transplantation 2007; 83:174-83. [PMID: 17264814 DOI: 10.1097/01.tp.0000250658.00925.c8] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Alloantigen specific T cells have been shown to be required for allograft rejection. The chemokine, stromal cell derived factor-1 (SDF-1) at high concentration, has been shown to act as a T-cell chemorepellent and abrogate T-cell infiltration into a site of antigen challenge in vivo via a mechanism termed fugetaxis or chemorepulsion. We postulated that this mechanism could be exploited therapeutically and that allogeneic cells engineered to express a chemorepellent protein would not be rejected. METHODS Allogeneic murine insulinoma beta-TC3 cells and primary islets from BALB/C mice were engineered to constitutively secrete differential levels of SDF-1 and transplanted into allogeneic diabetic C57BL/6 mice. Rejection was defined as the permanent return of hyperglycemia and was correlated with the level of T-cell infiltration. The migratory response of T-cells to SDF-1 was also analyzed by transwell migration assay and time-lapse videomicroscopy. The cytotoxicity of cytotoxic T cell (CTLs) against beta-TC3 cells expressing high levels of SDF-1 was measured in standard and modified chromium-release assays in order to determine the effect of CTL migration on killing efficacy. RESULTS Control animals rejected allogeneic cells and remained diabetic. In contrast, high level SDF-1 production by transplanted cells resulted in increased survival of the allograft and a significant reduction in blood glucose levels and T-cell infiltration into the transplanted tissue. CONCLUSIONS This is the first demonstration of a novel approach that exploits T-cell chemorepulsion to induce site specific immune isolation and thereby overcomes allograft rejection without the use of systemic immunosuppression.
Collapse
Affiliation(s)
- Natalia Papeta
- Infectious Diseases Medicine Division and Partner AIDS Research Center, Massachusetts General Hospital, Charlestown, MA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Shi Q, Wang D, Hadley GA, Farber DL, Bartlett ST. Abrogation of recurrent autoimmunity in the NOD mouse: A critical role for host interleukin 4. Surgery 2006; 140:281-8. [PMID: 16904981 DOI: 10.1016/j.surg.2006.05.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2006] [Revised: 04/27/2006] [Accepted: 05/06/2006] [Indexed: 11/20/2022]
Abstract
BACKGROUND We previously established a clinically relevant strategy to abrogate recurrent autoimmunity and enable long-term islet graft survival, involving antilymphocyte serum (ALS)-depletion of recipient T cells and intraportal administration of donor pancreatic lymph node cells (PLNCs) along with islet grafts. In this study, we investigated whether Th2 cytokines were required for the tolerizing ability of ALS/PLNC treatment in islet transplantation. METHODS ALS-treated diabetic NOD recipient mice, and NOD recipient mice deficient in interleukin 4 (IL-4-/-) or 10 (IL-4/10-/-) were transplanted with NOR or NOD.scid islets intraportally along with donor PLNC. Blood glucose levels were monitored to access graft function, sections of graft-bearing livers were histologically examined, and ELISPOT assays were used to assess cytokine profile and frequency of islet-reactive CD4 T cells. RESULTS We found that ALS/PLNC was not effective in prolonging islet graft survival in diabetic NOD hosts deficient in either IL-4 (NOD.IL-4-/-) or in IL-4 and IL-10 (NOD.IL4-/-/10-/-) (mean survival time, 36 days), contrasting the long-term survival of islet grafts in wild-type NOD mice (mean survival time, > 80 days). In contrast, PLNC deficient in IL-4 promoted long-term graft survival in wild-type NOD hosts similar to that in wild-type PLNC. In wild-type NOD recipients of either wild-type PLNC or IL-4-/- PLNC, the host autoantigen-specific CD4 T cells produced predominately IL-4 coincident with long-term graft survival, whereas, in NOD.IL-4-/- recipients with rejected grafts, the autoreactive T cells produced interferon gamma and low amounts of IL-4. CONCLUSIONS These data demonstrate that abrogation of recurrent autoimmunity requires host IL-4 and that manipulation of the autoreactive cytokine profile in long-term diabetes may be an effective strategy for islet transplant therapies.
Collapse
Affiliation(s)
- Qixin Shi
- Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201-1544, USA
| | | | | | | | | |
Collapse
|
5
|
Balamurugan AN, Bottino R, Giannoukakis N, Smetanka C. Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes. Pancreas 2006; 32:231-43. [PMID: 16628077 DOI: 10.1097/01.mpa.0000203961.16630.2f] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Pancreatic islet cell transplantation is an attractive treatment of type 1 diabetes (T1D). The success enhanced by the Edmonton protocol has fostered phenomenal progress in the field of clinical islet transplantation in the past 5 years, with 1-year rates of insulin independence after transplantation near 80%. Long-term function of the transplanted islets, however, even under the Edmonton protocol, seems difficult to accomplish, with only 10% of patients maintaining insulin independence 5 years after transplantation. These results differ from the higher metabolic performance achieved by whole pancreas allotransplantation, and autologous islet cell transplantation, and form the basis for a limited applicability of islet allografts to selected adult patients. Candidate problems in islet allotransplantation deal with alloimmunity, autoimmunity, and the need for larger islet cell masses. Employment of animal islets and stem cells, as alternative sources of insulin production, will be considered to face the problem of human tissue shortage. Emerging evidence of the ability to reestablish endogenous insulin production in the pancreas even after the diabetic damage occurs envisions the exogenous supplementation of islets to patients also as a temporary therapeutic aid, useful to buy time toward a possible self-healing process of the pancreatic islets. All together, islet cell transplantation is moving forward.
Collapse
Affiliation(s)
- A N Balamurugan
- Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | | | | | | |
Collapse
|
6
|
Shi Q, Wang D, Hadley GA, Bingaman AW, Bartlett ST, Farber DL. Long-term islet graft survival in NOD mice by abrogation of recurrent autoimmunity. Diabetes 2004; 53:2338-45. [PMID: 15331543 DOI: 10.2337/diabetes.53.9.2338] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Islet transplantation has great potential for curing type 1 diabetes; however, long-term islet survival using conventional immunosuppression remains elusive. We present a novel strategy for inducing long-lasting islet graft survival in diabetic NOD mice in the absence of posttransplant immunosuppression by initial treatment with antilymphocyte serum (ALS) followed by coadministration of donor pancreatic lymph node cells (PLNCs). When treated with ALS/PLNC, diabetic NOD mice become normoglycemic and tolerated minor antigen-disparate islet grafts for >100 days and syngeneic islet grafts indefinitely. Donor T-cells are required for graft prolongation, and tolerant hosts have long-term donor T-cell chimerism. Strikingly, host autoreactive T-cells from mice with long-surviving islet grafts predominantly produce interleukin-4, whereas autoreactive T-cells from mice that rejected their islet grafts predominantly produce interferon-gamma. We thus demonstrate a clinically relevant approach for ablation of recurrent autoimmunity in islet transplantation, involving donor lymphocyte-driven alteration of pathogenic autoreactive T-cells.
Collapse
Affiliation(s)
- Qixin Shi
- Division of Transplantation, Department of Surgery, University of Maryland School of Medicine, 29 South Greene St., Baltimore, MD 21201, USA
| | | | | | | | | | | |
Collapse
|
7
|
Makhlouf L, Kishimoto K, Smith RN, Abdi R, Koulmanda M, Winn HJ, Auchincloss H, Sayegh MH. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes 2002; 51:3202-10. [PMID: 12401711 DOI: 10.2337/diabetes.51.11.3202] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Although it has often been assumed that transplanted allogeneic islets can be destroyed by recurrent autoimmunity in recipients with type 1 diabetes, definitive evidence is lacking and the settings in which this may occur have not been defined. To address these issues, we compared the survival of islet transplants (subject to tissue-specific autoimmunity) with cardiac transplants (not subject to tissue-specific autoimmunity) from various major histocompatibility complex (MHC)-matched and -mismatched donors transplanted into autoimmune NOD recipients. We found that when recipients were treated with combined B7 and CD154 T-cell costimulatory blockade, hearts survived best with better MHC matching, whereas islets survived worst when the donor and recipient shared MHC class II antigens. In the absence of full or MHC class II matching, there was no difference in the survival of islet and cardiac allografts. We also found that the tendency of NOD mice to resist tolerance induction by costimulation blockade is mediated by both CD4+ and CD8+ T-cells, not directly linked to the presence of autoimmunity, and conferred by non-MHC background genes. These findings have clinical importance because they suggest that under some circumstances, avoiding MHC class II sharing may provide better islet allograft survival in recipients with autoimmune diabetes, since mismatched allogeneic islets may be resistant to recurrent autoimmunity. Our results may have implications for the design of future clinical trials in islet transplantation.
Collapse
Affiliation(s)
- Leila Makhlouf
- Laboratory of Immunogenetics and Transplantation, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
| | | | | | | | | | | | | | | |
Collapse
|
8
|
|
9
|
Tori M, Ito T, Yumiba T, Maeda A, Sawai T, Miyasaka M, Kiyono H, Matsuda H, Nozawa M, Shirakura R. Significant role of intragraft lymphoid tissues in preventing insulin-dependent diabetes mellitus recurrence in whole pancreaticoduodenal transplantation. Microsurgery 1999; 19:338-43. [PMID: 10586200 DOI: 10.1002/(sici)1098-2752(1999)19:7<338::aid-micr10>3.0.co;2-k] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Graft recurrence of insulin-dependent diabetes mellitus (IDDM) was examined. Islet transplantation or pancreas-alone transplantation excluding the duodenum and peripancreatic lymph nodes was compared with whole pancreaticoduodenal transplantation. A Wistar Furth (WF; RT1(u), RT6.2) to major histocompatibility complex (MHC)-compatible diabetes-prone (DP; RT1(u), RT6.1 gene carrier)-biobreeding (BB) rat transplantation model was used. Only DP recipients that had been transplanted with whole pancreaticoduodenal grafts were free from IDDM recurrence (>60 days postgrafting) when treated with anti-intercellular adhesion moluecule-1 (ICAM)-1/leukocyte function-associated antigen-1 (LFA-1) monoclonal antibodies (mAbs). In the spleen cells of the DP rats that had accepted pancreatic grafts (60 days postgrafting), flow cytometric analysis showed that NKR-P1(+)TCRalphabeta(+) (NKT) cells had proliferated markedly, with the proportion of 12.8 +/- 1.7% in the total splenic T cells, most of which (86.2%) were derived from the donor (RT6.2(+)). By enzyme-linked immunonosorbent assay (ELISA), serum interferon gamma (IFN-gamma) was not detected (<13 pg/ml) in all rats. However, interleukin-4 (IL-4) was detected as 158.8 +/- 28.0 pg/ml in the nonrecurrent DP recipients. These data suggested that to prevent IDDM recurrence in the pancreatic graft, the lymphocytes in the pancreaticoduodenal grafts are necessary. Also, the donor-derived NKT cells might have some immunoregulatory functions with a Th2 deviation.
Collapse
Affiliation(s)
- M Tori
- Division of Organ Transplantation, Department of Bioregulation, Biomedical Research Center, Osaka University Medical School, Osaka, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Allen EM, Bartlett ST. The effect of methimazole, iodine and splenocytes on thyroid transplants in BB/Wor rats. Transplantation 1999; 68:25-30. [PMID: 10428262 DOI: 10.1097/00007890-199907150-00006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND BB/Wor rats develop spontaneous autoimmune insulin-requiring diabetes mellitus and lymphocytic thyroiditis (LT). Our investigations examined the effect of the thyroid-specific agents, iodine and methimazole (MMI) on thyroid graft survival in BB/Wor rats, compared the intrathyroidal cytokine mRNA expression of endogenous and engrafted thyroids, and ascertained whether unfractionated splenocytes could protect thyroid grafts from lymphocytic infiltration. METHODS In study 1, 0.025% iodine water-treated LT-prone NB line BB/Wor rats were randomized to receive one of the following treatments: (1) 1.0 x 10(8) splenocytes, IV from LT-resistant WA line BB/Wor rats, (2) WA rat thyroid transplants, (3) both, or (4) neither (controls). In study 2, after thyroid transplantation, LT-prone BB/Wor rats were randomized to receive (1) WA splenocytes, (2) 0.025% iodine water, (3) 0.05% MMI water or, (4) tap water (controls). The incidence of LT was determined by microscopic inspection after hematoxylin and eosin staining. Lymphocytic infiltrates were characterized by immunohistochemistry. Cytokine mRNA was detected by RT-PCR. RESULTS Grafts from MMI-treated rats had a significantly lower incidence of lymphocytic infiltration (MMI: 2/5; Tap: 5/5; I 5/5, P<0.05, chi2). IL-10 mRNA was expressed in 77% (7/9) endogenous thyroids and 20% (1/5) of the transplanted WA thyroids (P<0.05, chi2) from iodine-treated rats with LT. There was no difference in IL-12 mRNA expression. Lymphocytic infiltration occurred in 100% of the splenocyte-treated graft recipients. Both endogenous and engrafted thyroids contained CD4 and C8 T cells with scattered IgG staining. CONCLUSION Target organ-specific interventions that suppress antigen presentation may have an adjunctive role in transplantation tolerance. The differential expression of IL-10 may indicate preferential Th2 lymphocyte activation in the endogenous tissues.
Collapse
Affiliation(s)
- E M Allen
- Department of Medicine University of Maryland Medical System and Baltimore VA Medical Center, 21201-1595, USA
| | | |
Collapse
|
11
|
Lu X, Borel JF. Requirement of CD4 cells for induction and maintenance of unresponsiveness in islet xenografted mice. Xenotransplantation 1998; 5:207-14. [PMID: 9741459 DOI: 10.1111/j.1399-3089.1998.tb00029.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Long-term survival of islet xenografts in the hamster to mouse model can be induced by a short-course treatment with a nondepleting anti-CD4 mAb but not with a depleting anti-CD4 mAb [Lu et al. Xenotransplantation 1998; 5:154-163]. Although CD4 cells are known to play a key role in the rejection of islet xenografts, it remains unclear whether CD4 cells are also required for the induction and/or maintenance of specific unresponsiveness to xenografts. To investigate this problem, islets were isolated from golden hamsters and transplanted into streptozotocin-induced diabetic CBA/J mice. Nondepleting mAb YTS 177.9 was used to block CD4 cells for the induction of islet xenograft unresponsiveness and subsequently depleting mAb GK1.5 to deplete CD4 cells in the unresponsive recipients. First, we now confirm that second donor-strain xenografts were permanently accepted in recipients that had been unresponsive to the first grafts, whereas Lewis rat islet xenografts, used as third-party grafts, were rejected like a primary graft within 7-8 days. Second, we depleted CD4 cells in recipient mice, which had been treated perioperatively with the nondepleting mAb YTS 177.9 and became unresponsive to their primary hamster islet graft, by using a depleting anti-CD4 mAb at different time points post-transplant. Depletion of CD4 cells in the unresponsive recipients by the depleting anti-CD4 mAb GK1.5 did abrogate this unresponsive state, since the grafts were always rejected within an average of 25.5 days after the mAb GK1.5 injections. Therefore, our results strongly suggest that CD4 positive cells play an active suppressive role and that their presence in the recipients appears essential for both induction and maintenance of long-term islet xenograft survival or specific unresponsiveness.
Collapse
Affiliation(s)
- X Lu
- Novartis Pharma, Inc., Transplantation Research, Basel, Switzerland
| | | |
Collapse
|
12
|
Suzuki K, Yan H, Li XK, Amemiya H, Suzuki S, Kimura H. Prevention of recurrence of autoimmune diabetes type I in rats following pancreaticoduodenal transplantation. Transplant Proc 1998; 30:1071-2. [PMID: 9636434 DOI: 10.1016/s0041-1345(98)00156-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- K Suzuki
- Department of Research Surgery, National Children Medical Research Center, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
13
|
Drachenberg CB, Papadimitriou JC, Klassen DK, Weir MR, Bartlett ST. Distribution of alpha and beta cells in pancreas allograft biopsies: correlation with rejection and other pathologic processes. Transplant Proc 1998; 30:665-6. [PMID: 9532226 DOI: 10.1016/s0041-1345(97)01455-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- C B Drachenberg
- Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
| | | | | | | | | |
Collapse
|
14
|
Affiliation(s)
- M G von Herrath
- The Scripps Research Institute, Division of Virology, La Jolla, CA 92037, USA
| |
Collapse
|